-
1دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
2دورية أكاديمية
المؤلفون: Wafa Gati, Mohamed M. Rammah, Mohamed B. Rammah, Gwilherm Evano
المصدر: Beilstein Journal of Organic Chemistry, Vol 8, Iss 1, Pp 2214-2222 (2012)
مصطلحات موضوعية: carbolithiation, carbometallation, dihydropyridines, organolithium reagents, pyridines, sarizotan, ynamides, Science, Organic chemistry, QD241-441
وصف الملف: electronic resource
Relation: https://doaj.org/toc/1860-5397
-
3دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
4دورية أكاديمية
المؤلفون: Gerlach, Manfred, Bartoszyk, Gerd D., Riederer, Peter, Dean, Olivia, van den Buuse, Maarten
المصدر: Journal of Neural Transmission: Basic Neurosciences, Genetics and Immunology, Movement disorders, Dementias, Biological Psychiatry, Biological Child and Adolescent Psychiatry. December 2011 118(12):1733-1742
-
5دورية أكاديمية
المؤلفون: Marin, C., Aguilar, E., Rodríguez-Oroz, M. C., Bartoszyk, G. D., Obeso, J. A.
المصدر: Psychopharmacology. June 2009 204(2):241-250
-
6
المؤلفون: Christopher E. Dempsey, Andrew F. James, Ana Paula Abdala, Hongwei Cheng, Yihong Zhang, Jules C. Hancox, Chunyun Du
المصدر: Journal of Molecular and Cellular Cardiology
Cheng, H, Zhang, Y, Du, C, James, A F, Dempsey, C E, Abdala, A P & Hancox, J C 2019, ' Potent hERG channel inhibition by sarizotan, an investigative treatment for Rett Syndrome ', Journal of molecular and cellular cardiology . https://doi.org/10.1016/j.yjmcc.2019.07.012
Cheng, H, Du, C, Zhang, Y, James, A, Dempsey, C, Abdala, A P & Hancox, J 2019, ' Potent hERG channel inhibition by sarizotan, an investigative treatment for Rett Syndrome ', Journal of Molecular and Cellular Cardiology, vol. 135, pp. 22-30 . https://doi.org/10.1016/j.yjmcc.2019.07.012مصطلحات موضوعية: 0301 basic medicine, Agonist, Male, congenital, hereditary, and neonatal diseases and abnormalities, medicine.drug_class, Long QT syndrome, Heart Ventricles, hERG, Guinea Pigs, Respiratory System, Action Potentials, Rett syndrome, Sarizotan, 030204 cardiovascular system & hematology, Pharmacology, QT interval, Article, Ventricular action potential, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Transcriptional Regulator ERG, Risk Factors, long QT syndrome, Rett Syndrome, Medicine, Animals, Humans, Myocytes, Cardiac, KCNH2, cardiovascular diseases, Organic Chemicals, Molecular Biology, sarizotan, biology, business.industry, medicine.disease, Potassium channel, Ether-A-Go-Go Potassium Channels, 030104 developmental biology, HEK293 Cells, chemistry, Gene Expression Regulation, biology.protein, Cardiology and Cardiovascular Medicine, business
وصف الملف: application/pdf
-
7دورية أكاديمية
المؤلفون: Krösser, Sonja, Neugebauer, Roland, Dolgos, Hugues, Fluck, Markus, Rost, Karl-Ludwig, Kovar, Andreas
المصدر: European Journal of Clinical Pharmacology. April 2006 62(4):277-284
-
8دورية أكاديمية
المؤلفون: Kuenzel, Heike E., Steiger, Axel, Held, Katja, Antonijevic, Irina A., Frieboes, Ralf-Michael, Murck, Harald
المصدر: Psychopharmacology. July 2005 180(2):327-332
-
9دورية أكاديمية
المؤلفون: Bartoszyk, G. D., van Amsterdam, C., Greiner, H. E., Rautenberg, W., Russ, H., Seyfried, C. A.
المصدر: Journal of Neural Transmission: Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry. February 2004 111(2):113-126
-
10
المؤلفون: Shih-Ya Hung, E. Maruthi Prasad
المصدر: Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 717, p 717 (2021)مصطلحات موضوعية: 0301 basic medicine, Drug, Oncology, plasma therapy, medicine.medical_specialty, Levodopa, Parkinson's disease, media_common.quotation_subject, Pharmaceutical Science, Review, Disease, Sarizotan, 03 medical and health sciences, chemistry.chemical_compound, Pharmacy and materia medica, α-synuclein, 0302 clinical medicine, Internal medicine, Drug Discovery, medicine, levodopa, media_common, clinical trials, business.industry, medicine.disease, gene therapy, dopamine receptor agonists, RS1-441, Clinical trial, 030104 developmental biology, Dyskinesia, chemistry, Carbidopa, Parkinson’s disease, Medicine, Molecular Medicine, medicine.symptom, business, 030217 neurology & neurosurgery, medicine.drug